Aim:
To
evaluate
the
prediction
ability
for
quantitative
computed
tomography
(QCT)-based
metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD)
of
four
widely
known
hepatic
steatosis
algorithms,
namely
index
(FLI),
(HSI),
Framingham
Steatosis
(FSI)
and
Zhejiang
University
(ZJU
index).
Methods:
From
July
2020
to
June
2022,
health
checkup
subjects
who
accepted
fat
quantification
with
QCT
at
Health
Management
Center
Second
Affiliated
Hospital
Chongqing
Medical
were
recruited
in
this
study.
MAFLD
was
diagnosed
by
using
QCT-based
quantification.
The
performance
FLI,
HSI,
FSI,
ZJU
on
evaluated
area
under
receiver
operating
characteristic
curve
(AUC).
Results:
Of
a
total
4,566
enrolled
study,
48.7%
MAFLD.
AUC
values
0.819,
0.792,
0.822
0.826,
respectively.
FLI
exhibited
highest
sensitivity
(SN)
79.42%,
while
demonstrated
specificity
(SP)
75.35%.
Conclusions:
All
indices
(FLI,
index)
have
acceptable
predictive
patients
Our
study
suggests
that
above
stable
detecting
European Journal of Clinical Investigation,
Journal Year:
2024,
Volume and Issue:
54(11)
Published: June 28, 2024
Abstract
Background
Numerous
recent
studies
have
explored
the
association
between
metabolic
dysfunction‐associated
steatotic
liver
disease
(MASLD)
and
risk
of
various
extrahepatic
cancers.
However,
conclusions
were
inconclusive.
The
aim
this
study
was
to
clarify
relationship
by
conducting
a
robust
meta‐analysis.
Methods
Systematic
searches
conducted
on
PubMed,
Embase
Web
Science
databases
identify
relevant
cohort
published
prior
February
2024.
Hazard
ratios
(HRs)
their
corresponding
95%
confidence
intervals
(95%
CIs)
combined
using
random‐effects
model
in
Results
Eighteen
(approximately
16.7
million
participants)
finally
included
MASLD
linked
higher
cancers,
such
as
gastric
(
n
=
10,
HR
1.47,
CI:
1.07–2.01),
colorectal
13,
1.33,
1.16–1.53),
pancreatic
8,
1.41,
1.11–1.79),
biliary
tract
5,
1.27,
1.18–1.37),
thyroid
6,
1.46,
1.02–2.09),
urinary
system
1.45,
1.25–1.69),
breast
11,
1.17,
1.08–1.26)
female
genital
organ
cancers
1.36,
1.11–1.66).
there
no
statistically
significant
head
neck
1.03,
99–1.07),
oesophageal
9,
1.26,
0.86–1.86),
lung
1.01,
0.92–1.10),
prostate
1.06,
0.94–1.19)
or
small
intestine
cancer
2,
1.75,
1.00–3.06).
Conclusions
This
latest
large‐scale
meta‐analysis
indicated
that
associated
with
an
increased
gastric,
colorectal,
pancreatic,
duct,
thyroid,
system,
breast,
skin
Further
research
is
needed
investigate
mechanisms
underlying
these
associations.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: July 9, 2024
Background
and
aims
In
recent
years,
the
relationship
between
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
colorectal
cancer
(CRC)
or
adenoma
(CRA)
has
gained
widespread
attention.
Previous
meta-analyses
on
this
subject
either
incorporated
numerous
cross-sectional
studies,
which
were
susceptible
to
bias,
concentrated
solely
a
restricted
number
of
cohort
studies.
Moreover,
with
release
substantial
high-quality
studies
in
past
two
findings
continue
be
debated
contradictory.
Therefore,
we
conducted
an
updated
systematic
review
meta-analysis
quantitatively
evaluate
magnitude
association
them.
Methods
Comprehensive
searches
PubMed,
Web
Science,
Embase
without
language
restrictions
from
time
their
creation
up
December,
2023.
The
pooled
hazard
ratios
(HRs)
95%
confidence
interval
(CIs)
calculated
by
generic
inverse
variance
based
random-effects
model.
subgroup
sensitivity
analyses
performed.
Results
A
total
15
analyzed
meta-analysis,
included
9,958,412
participants.
13
showed
that
MASLD
was
linked
higher
risk
CRC
(HR=1.25,
CI:
1.15-1.36,
P
<
0.00001).
Additionally,
further
analysis
indicated
combined
HR
remained
consistent
regardless
study
location,
nomenclature
fatty
(FLD),
confirmation
methods
for
FLD,
sample
size,
follow-up
time,
quality.
Furthermore,
four
demonstrated
correlated
increased
CRA
(HR=1.38,
1.17-1.64,
=
0.0002).
results
validated
robustness
aboved
findings.
Conclusion
our
associated
incident
CRC/CRA.
future,
it
is
necessary
conduct
more
prospective
thoroughly
assess
potential
confounding
factors,
particularly
individuals
Europe
North
America.
related
mechanism
should
enhance
understanding
link
Systematic
registration
Open
Science
Framework
registries
(
https://osf.io/m3p9k
).
Thyroid,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 18, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
represents
a
hepatic
manifestation
of
metabolic
syndrome.
This
study
investigated
the
association
between
newly
developed
nomenclature
MASLD
and
risk
thyroid
cancer
in
Korean
population.
Metabolism and Target Organ Damage,
Journal Year:
2024,
Volume and Issue:
4(1)
Published: Feb. 22, 2024
A
recent
study
by
Crudele
et
al.
reported
on
the
association
between
surrogate
indices
of
liver
fibrosis
and
risk
gynecological
cancers
among
dysmetabolic
women.
To
put
this
in
context,
notions
regarding
sex
dimorphism
nonalcoholic
fatty
disease
(NAFLD)
are
discussed.
Additionally,
meta-analytic
reviews
extrahepatic
reviewed.
Next,
I
discuss
relationship
metabolic
dysfunction-associated
(MAFLD)
with
cancers,
notably
including
breast
female
reproductive
systems
humans.
The
pathomechanisms
potentially
accounting
for
include
genetics,
deregulated
hormones,
chronic
subclinical
inflammatory
state,
milieu,
oxidative
stress,
gut
dysbiosis,
environmental
pollution,
altered
immune
surveillance.
